Generic Name: inclisiran
Brand Name: TBC
Manufacturer: Novartis Pharmaceuticals Canada Inc.
Therapeutic Area: Primary hypercholesterolemia
Indications: Inclisiran is indicated in adults with primary hypercholesterolemia (heterozygous familial and non-familial), as an adjunct to diet: • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach low density lipoprotein cholesterol (LDL-C) goals with the tolerated dose of a statin or, • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
Manufacturer Requested Reimbursement Criteria1: As an adjunct to diet and maximally tolerated statin (MTS) therapy with or without other lipid‐lowering therapies (LLT) in adults with heterozygous familial hypercholesterolemia (HeFH) or patients who have had prior cardiovascular (CV) events and require additional lowering of LDL‐C.
Submission Type: Initial
Project Status: Pending
Call for patient/clinician input open: February 17, 2021
Call for patient/clinician input closed: April 9, 2021
Anticipated Date: March 17, 2021
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.